Salud Digna, one of Mexico’s largest medical networks, is using South Korean firm Lunit’s AI-powered medical imaging technology at more than 230 clinics across Mexico and Central America.

Lunit provides AI-powered technology for cancer diagnostics and therapeutics.

As part of the arrangement, Lunit will gain access to Salud Digna’s database, comprising millions of deidentified 2D mammography and chest X-ray images. These high-quality data should help Lunit refine its AI algorithms, particularly for the Latin American market.

The deal centres on two of Lunit’s flagship products: the Insight CXR AI-powered chest X-ray analyser; and Insight MMG AI software for mammography analysis. These tools are set to enhance diagnostic capabilities for Salud Digna, which treats approximately 20 million patients annually.

“By integrating Lunit’s advanced AI into our healthcare network, we aim to improve the accuracy and efficiency of our imaging services,” said Juan Carlos Ordoñez, CEO of Salud Digna (www.salud-digna.org). “Together, we are committed to leveraging our extensive data resources to drive innovation in medical imaging and ultimately improve patient care across the region.”

The collaboration extends beyond a traditional supplier-client relationship. Lunit and Salud Digna will engage in joint research projects, leveraging the shared data to advance medical imaging AI technology and showcase the impact of this partnership on healthcare delivery in Mexico and across the Latin American region. 

“This multifaceted partnership with Salud Digna marks a milestone in our global expansion and our mission to improve patient outcomes through AI,” said Brandon Suh, CEO of Lunit. “By combining our cutting-edge AI technology with Salud Digna’s vast clinical experience and extensive patient data, we’re not just supplying software, we’re collaborating to advance medical imaging AI technology tailored to the needs of patients in Mexico and potentially the broader Latin American region.”

Founded in 2013, Lunit (lunit.io) harnesses AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. Its FDA-cleared Insight suite for cancer screening serves over 4500 hospitals and medical institutions across more than 55 countries.

In 2024, Lunit acquired Volpara Health Technologies, setting the stage for synergy and accuracy, particularly in breast health and screening technologies.

Lunit is headquartered in Seoul, South Korea, with a network of offices worldwide.